for the referral!

## Checklist for Cimzia Lyo (certolizumab pegol) Referral

Required documentation for all initial referrals

|         |  | 71                  | equired documentation                                 | m jor un miliar rejel | 1413  |  |
|---------|--|---------------------|---|-----------------------|---|--|
| Patient | ·  |                     | DOB   | Date                  | New Start  Maintenance  |  |
| Please  | return <b>complet</b>  | ed checklist and    | checklist items for an i                              | nfusion referral:     |   |  |
|         | Patient demographics (e.g. address, phone number, SSN, etc.)   |                     |   |                       |   |  |
|         | Insurance information and copy of insurance card(s). Please indicate the insurance that is primary, and the insurance that is secondary, if applicable, and the subscriber's date of birth.  o If insurance requires prior authorization, please provide the phone number and allow up to 15-30 days for this to be completed by one of our Infusion Coordinators.   |                     |   |                       |   |  |
|         | Signed and completed Cimzia Standard Order (our order form) with ICD diagnosis code  o Standard Order forms are available at lowcountryrheumatology.com/infusions/   |                     |   |                       |   |  |
|         | Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes or contraindications to conventional therapy, and how long patient has been on Cimzia Lyo.   |                     |   |                       |   |  |
|         | Lab results and/or tests to support diagnosis.  • Pre-Screening:  • Required TB screening results: PPD (within 1 year) or QuantiFERON Gold Test (within 3 years)  • Required Hepatitis screening (within 1 year): Hepatitis B Surface Antigen, Hepatitis B Surface Antibody, or Hepatitis B Core Antibody results and Hepatitis C Antibody results  • Lab results within last 30 days: CBC  • Most recent Rapid 3 (if available) |                     |   |                       |   |  |
|         | Please indicate name and direct phone number of a contact within your office that we can speak with to obtain any additional information:  O Name:   |                     |   |                       |   |  |
|         | o Phone  | Number:             |   |                       |   |  |
|         |  | Рар                 | erwork can be faxed                                   | to (843)-793-6181     |   |  |
|         |  | Infusion Coo        | rdinators can assist<br>(843)-572-8                   |                       | stions at   |  |
|         | Please mark pref   |                     | r Country Rheumatology<br>ve will do our best to acco |                       | e cannot make any guarantees.   |  |
|         |  | 2001                | Summervi<br>2nd Ave, Suite 201, Sui                   |                       |   |  |
|         |  | 1100                | Mount Pleas<br>Johnnie Dodds Blvd, Mi                 |                       |   |  |
|         |  | 1100                | West Ashl   | •                     |   |  |
|         |  | 2291 H              | enry Tecklenburg Drive                                | •                     | 4   |  |
| docume  | entation to the p  | patient's insurance | e company for eligibility                             | . Our Infusion Coord  | submit all required clinical inators will notify you if any further NP to obtain H&P for chart. We will |  |

Low Country Rheumatology Use Only Existing Patient Yes\_\_\_\_ No\_\_\_\_ Physician \_\_\_\_\_

review financial responsibility with the patient and refer them to any available co-pay assistance as required. Thank you

## Standard Orders for Cimzia Lyo (certolizumab pegol) Administration

| Patient   | DOBDate  |                                    |  |  |  |  |  |
|---|--|------------------------------------|--|--|--|--|--|
|   | if they have suspected infectious process or is a super infection related to its effect on the imm |                                    |  |  |  |  |  |
| Indication:   |  |                                    |  |  |  |  |  |
| ☐ M05.79 RA with rheumatoid factor of multiple sites w/o organ involvement  | $\hfill \square$ M06.09 RA w/o rheumatoid factor, multiple sites                                   | ☐ L40.50 Arthropathic psoriasis    |  |  |  |  |  |
| ☐ L40.59 Other psoriatic arthropathy  | ☐ M45.9 Ankylosing spondylitis, unspecified site in spine  | ☐ Crohn's disease, please specify: |  |  |  |  |  |
| ☐ L40.0 Plaque Psoriasis  |  |                                    |  |  |  |  |  |
| History:  |  |                                    |  |  |  |  |  |
| □ Inadequate response to DMARD  |  |                                    |  |  |  |  |  |
| □ Rapid 3   | □ Swollen/tender joints  |                                    |  |  |  |  |  |
| □ ESR/CRP   | <ul> <li>□ Progressive erosive arthropathy</li> <li>□ Recent or upcoming surgery</li> </ul>        |                                    |  |  |  |  |  |
| □ HBsAg, HBsAb, HB core Ab, HCAb □ History of skin cancer   | □ Necent of apconning surgery  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
| Dose:  □ Loading dose Cimzia 400mg SQ at weeks 0  | , 2, and 4 then every 4 weeks  |                                    |  |  |  |  |  |
|   | ·  |                                    |  |  |  |  |  |
| □ Loading dose Cimzia 400mg SQ at weeks 0, 2, and 4 then Cimzia 200mg SQ every 2 weeks  Additional orders/comments: |  |                                    |  |  |  |  |  |
| Additional orders, comments.  |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
|   |  |                                    |  |  |  |  |  |
| Practice Name:  | NPI:   |                                    |  |  |  |  |  |
| Physician Name:   | State License:   |                                    |  |  |  |  |  |
| Physician Signature:  | DEA #:   |                                    |  |  |  |  |  |
| Date:   | UPIN:  |                                    |  |  |  |  |  |